QuartataWeb
Home  |   About  |   Theory  |   Tutorials  |   FAQ  |   Bahar Lab  |   Statistics
 

Network of interactions between drugs (red spheres) and targets (blue spheres) is displayed above.
The red lines are used for the predicted interactions and the thickness of edges indicate the confidence score of predictions.

Data source: DrugBank-all; Query type: target; # of requested predictions: 20; Secondary interactions: no
Input target 1: P09871
No. Gene UniProt ID Protein Name Pathway PDB
1 C1S P09871 Complement C1s subcomponent hsa04610; hsa05133; hsa05150; hsa05322 1ELV; 1NZI; 4J1Y; 4LMF; 4LOR; 4LOS; 4LOT


15 known interactions (drugs) of input target (C1S): Complement C1s subcomponent
No. Group Type Drug ID Drug Name SMILES
⇨ TargetHunter		 Image
1 Approved;
Investigational		 BiotechDrug DB00074 Basiliximab Thumb
2 Approved;
Investigational		 BiotechDrug DB00072 Trastuzumab Thumb
3 Experimental SmallMoleculeDrug DB02371 2-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Ethanesulfonic Acid Thumb
4 Approved;
Investigational		 SmallMoleculeDrug DB01593 Zinc Thumb
5 Approved;
Investigational		 SmallMoleculeDrug DB09130 Copper Thumb
6 Approved BiotechDrug DB00002 Cetuximab Thumb
7 Approved BiotechDrug DB00054 Abciximab Thumb
8 Approved BiotechDrug DB00051 Adalimumab Thumb
9 Approved;
Investigational		 BiotechDrug DB00078 Ibritumomab tiuxetan Thumb
10 Approved;
Investigational		 BiotechDrug DB09228 Conestat alfa Thumb
11 Approved BiotechDrug DB06404 Human C1-esterase inhibitor Thumb
12 Approved;
Investigational		 BiotechDrug DB00005 Etanercept Thumb
13 Approved;
Investigational		 BiotechDrug DB00075 Muromonab Thumb
14 Approved;
Investigational		 BiotechDrug DB00056 Gemtuzumab ozogamicin Thumb
15 Approved BiotechDrug DB00073 Rituximab Thumb


20 predicted interactions (drugs) of input target (C1S): Complement C1s subcomponent
No. Group Type Drug ID Drug Name SMILES
⇨ TargetHunter		 Image Confidence score
1 Approved;
Investigational		 BiotechDrug DB00081 Tositumomab Thumb 75.3%
2 Investigational;
Withdrawn		 BiotechDrug DB00111 Daclizumab Thumb 73.5%
3 Approved;
Investigational		 BiotechDrug DB00087 Alemtuzumab Thumb 73.3%
4 Approved;
Investigational		 BiotechDrug DB00110 Palivizumab Thumb 72.6%
5 Approved;
Investigational		 BiotechDrug DB00095 Efalizumab Thumb 69.3%
6 Approved;
Investigational		 BiotechDrug DB00112 Bevacizumab Thumb 67.0%
7 Approved;
Investigational		 BiotechDrug DB00028 Immune Globulin Human Thumb 66.3%
8 Approved;
Investigational		 BiotechDrug DB00108 Natalizumab Thumb 64.0%
9 Approved;
Investigational;
Withdrawn		 BiotechDrug DB00092 Alefacept Thumb 63.5%
10 Approved;
Investigational		 BiotechDrug DB11767 Sarilumab Thumb 55.2%
11 Approved;
Investigational;
Withdrawn		 BiotechDrug DB06607 Catumaxomab Thumb 55.0%
12 Approved;
Investigational		 SmallMoleculeDrug DB11638 Artenimol Thumb 47.4%
13 Approved;
Investigational		 SmallMoleculeDrug DB00707 Porfimer sodium Thumb 40.4%
14 Experimental SmallMoleculeDrug DB04395 Phosphoaminophosphonic Acid-Adenylate Ester Thumb 33.6%
15 Approved;
Investigational		 SmallMoleculeDrug DB00992 Methyl aminolevulinate Thumb 31.9%
16 Approved;
Investigational		 BiotechDrug DB12023 Benralizumab Thumb 29.3%
17 Approved BiotechDrug DB00098 Antithymocyte immunoglobulin (rabbit) Thumb 27.9%
18 Investigational SmallMoleculeDrug DB12831 Gabexate Thumb 24.3%
19 Approved;
Investigational		 BiotechDrug DB00004 Denileukin diftitox Thumb 24.3%
20 Approved;
Investigational		 SmallMoleculeDrug DB12598 Nafamostat Thumb 23.9%


  logl

Reference:  Hongchun Li, Fen Pei, D. Lansing Taylor and Ivet Bahar. (2020) QuartataWeb: Integrated Chemical–Protein-Pathway Mapping for Polypharmacology and Chemogenomics. Bioinformatics 36(12), 3935–3937.

Contact:

The QuartataWeb server is maintained by the Bahar Lab at the Department of Computational & Systems Biology at the University of Pittsburgh, School of Medicine, and sponsored by the NIH awards P41 GM103712 and P01 DK096990; and by the Li Lab at Research Center for Computer-Aided Drug Discovery at Shenzhen Institutes of Advanced Technology, CAS.

For questions and comments please contact Hongchun Li.